Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
[waldenström macroglobulinemia]
The
B-
lymphocyte
stimulator
(
BLYS
)
protein
is
known
to
regulate
immunoglobulin
in
normal
B
cells
,
and
be
overexpressed
in
B-
cell
malignancies
,
including
Waldenstrom
macroglobulinemia
(
WM
)
.
This
trial
evaluated
the
safety
and
activity
of
belimumab
,
a
monoclonal
antibody
targeting
BLYS
,
in
12
patients
with
WM
in
a
single
-arm
phase
II
study
.
Ten
patients
had
stable
disease
with
therapy
,
although
no
objective
responses
were
seen
.
Correlative
studies
showed
patients
to
have
low
or
undetectable
baseline
serum
levels
of
BLYS
,
Â
with
the
administration
of
belimumab
having
no
effect
on
B-
cell
numbers
.
Belimumab
can
not
be
recommended
as
a
single
-
agent
therapy
for
the
treatment
of
symptomatic
WM
,
although
further
evaluation
in
combination
with
other
agents
would
be
justified
.
Diseases
Validation
Diseases presenting
"waldenstrom macroglobulinemia"
symptom
waldenström macroglobulinemia
This symptom has already been validated
